Revvity [RVTY] vs Exact Sciences [EXAS] Detailed Stock Comparison
Revvity
NYSE
Loading...
Exact Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Revvity wins in 14 metrics, Exact Sciences wins in 5 metrics, with 0 ties. Revvity appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Revvity | Exact Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 37.76 | -7.33 | Exact Sciences |
| Price-to-Book Ratio | 1.35 | 3.14 | Revvity |
| Debt-to-Equity Ratio | 44.66 | 102.73 | Revvity |
| PEG Ratio | 16.83 | -120.56 | Exact Sciences |
| EV/EBITDA | 14.99 | 120.57 | Revvity |
| Profit Margin (TTM) | 10.19% | -34.19% | Revvity |
| Operating Margin (TTM) | 14.49% | 0.34% | Revvity |
| EBITDA Margin (TTM) | 14.49% | 0.34% | Revvity |
| Return on Equity | 3.61% | -35.51% | Revvity |
| Return on Assets (TTM) | 2.07% | -1.39% | Revvity |
| Free Cash Flow (TTM) | $541.65M | $74.55M | Revvity |
| Dividend Yield | 0.30% | N/A | N/A |
| 1-Year Return | -26.87% | -28.10% | Revvity |
| Price-to-Sales Ratio (TTM) | 3.60 | 2.64 | Exact Sciences |
| Enterprise Value | $12.59B | $9.44B | Revvity |
| EV/Revenue Ratio | 4.50 | 3.21 | Exact Sciences |
| Gross Profit Margin (TTM) | 54.50% | 69.35% | Exact Sciences |
| Revenue per Share (TTM) | $23 | $16 | Revvity |
| Earnings per Share (Diluted) | $2.30 | $-5.45 | Revvity |
| Beta (Stock Volatility) | 0.92 | 0.93 | Revvity |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Revvity vs Exact Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Revvity | 0.44% | -1.58% | -13.73% | -6.52% | -24.38% | -22.46% |
| Exact Sciences | -5.03% | -14.18% | -23.44% | -22.75% | -21.74% | -28.00% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Revvity | -26.87% | -45.01% | -26.56% | 71.89% | 305.04% | 324.65% |
| Exact Sciences | -28.10% | -4.03% | -51.96% | 78.68% | 853.26% | 1,579.92% |
Performance & Financial Health Analysis: Revvity vs Exact Sciences
| Metric | RVTY | EXAS |
|---|---|---|
| Market Information | ||
| Market Cap | $10.08B | $7.76B |
| Market Cap Category | Large cap | Mid cap |
| 10 Day Avg. Volume | 1,688,530 | 4,605,740 |
| 90 Day Avg. Volume | 1,365,820 | 3,261,747 |
| Last Close | $86.84 | $40.99 |
| 52 Week Range | $85.12 - $129.50 | $38.81 - $72.83 |
| % from 52W High | -32.94% | -43.72% |
| All-Time High | $203.16 (Dec 27, 2021) | $159.54 (Jan 25, 2021) |
| % from All-Time High | -57.26% | -74.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.16% |
| Quarterly Earnings Growth | -0.03% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | -0.34% |
| Operating Margin (TTM) | 0.14% | 0.00% |
| Return on Equity (TTM) | 0.04% | -0.36% |
| Debt to Equity (MRQ) | 44.66 | 102.73 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $64.29 | $13.05 |
| Cash per Share (MRQ) | $8.44 | $4.53 |
| Operating Cash Flow (TTM) | $584.59M | $305.61M |
| Levered Free Cash Flow (TTM) | $531.58M | $140.26M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.30% | N/A |
| Last 12-Month Dividend | $0.28 | N/A |
Valuation & Enterprise Metrics Analysis: Revvity vs Exact Sciences
| Metric | RVTY | EXAS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 37.76 | -7.33 |
| Forward P/E | 16.83 | -120.56 |
| PEG Ratio | 16.83 | -120.56 |
| Price to Sales (TTM) | 3.60 | 2.64 |
| Price to Book (MRQ) | 1.35 | 3.14 |
| Market Capitalization | ||
| Market Capitalization | $10.08B | $7.76B |
| Enterprise Value | $12.59B | $9.44B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.50 | 3.21 |
| Enterprise to EBITDA | 14.99 | 120.57 |
| Risk & Other Metrics | ||
| Beta | 0.92 | 0.93 |
| Book Value per Share (MRQ) | $64.29 | $13.05 |
Financial Statements Comparison: Revvity vs Exact Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RVTY | EXAS |
|---|---|---|
| Revenue/Sales | $664.76M | $706.79M |
| Cost of Goods Sold | $289.22M | $206.24M |
| Gross Profit | $375.55M | $500.55M |
| Research & Development | $53.60M | $105.31M |
| Operating Income (EBIT) | $72.23M | $-89.76M |
| EBITDA | $172.95M | $-36.86M |
| Pre-Tax Income | $52.38M | $-100.99M |
| Income Tax | $10.71M | $224,000 |
| Net Income (Profit) | $42.24M | $-101.22M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RVTY | EXAS |
|---|---|---|
| Cash & Equivalents | $1.14B | $347.13M |
| Total Current Assets | $2.32B | $1.37B |
| Total Current Liabilities | $648.19M | $502.47M |
| Long-Term Debt | $3.33B | $2.49B |
| Total Shareholders Equity | $7.64B | $2.40B |
| Retained Earnings | $5.88B | $-4.60B |
| Property, Plant & Equipment | $660.38M | $126.66M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RVTY | EXAS |
|---|---|---|
| Operating Cash Flow | $172.05M | $-36.98M |
| Capital Expenditures | N/A | $-31.17M |
| Free Cash Flow | $112.17M | $-365,000 |
| Debt Repayment | N/A | $-249.17M |
| Common Stock Repurchase | $-153.59M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | RVTY | EXAS |
|---|---|---|
| Shares Short | 6.05M | 7.47M |
| Short Ratio | 5.76 | 2.55 |
| Short % of Float | 0.07% | 0.05% |
| Average Daily Volume (10 Day) | 1,688,530 | 4,605,740 |
| Average Daily Volume (90 Day) | 1,365,820 | 3,261,747 |
| Shares Outstanding | 120.65M | 185.62M |
| Float Shares | 116.90M | 187.46M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.98% | 0.99% |
Dividend Analysis & Yield Comparison: Revvity vs Exact Sciences
| Metric | RVTY | EXAS |
|---|---|---|
| Last 12-Month Dividend | $0.28 | N/A |
| Last 12-Month Dividend Yield | 0.30% | N/A |
| 3-Year Avg Annual Dividend | $0.28 | N/A |
| 3-Year Avg Dividend Yield | 0.06% | N/A |
| 3-Year Total Dividends | $0.84 | N/A |
| Ex-Dividend Date | Apr 17, 2025 | N/A |